# Strategic Transition: KOMPOSOS-III-LAMBDA-max-3D-chem INTO KOMPOSOS-IV-PHARM
## Building Patient-Specific Cancer Drug Discovery via Categorical Runtime

### 1. Executive Summary

**Objective:** Transition KOMPOSOS-III-LAMBDA-max-3D-chem (materials science) into KOMPOSOS-IV-PHARM (pharmaceutical) to build a **patient-specific cancer drug discovery engine**.

**Why:**
- CHEM has proven 259-pair validated ground truth (95.4% accuracy) and domain-specific optimizations (dynamic potentials, Flory-Huggins χ, formation energy)
- PHARM has categorical runtime, clinical pipeline, patient stratification, and COG interference detection
- **Together:** Materials formulation + drug targeting + patient constraints = precision oncology

**Not a theoretical merger.** Concrete path:
1. Port CHEM's 7 bridges (battery, polymer, metal, ceramic, semiconductor, glass, molecular) into PHARM's Bridge ABC
2. Add patient profile as a categorical object with genomic metadata
3. Create drug-disease-patient morphisms with patient-specific weights
4. Wire COG to detect dangerous drug-drug interactions for *that patient*
5. Use game theory (OPTIMUS) to find Nash equilibrium of efficacy/toxicity/cost for *that patient*
6. Stream updates as new lab results arrive (streaming Kan extensions)

---

### 2. Why PHARM's Categorical Runtime is Necessary for Patient-Specific Oncology

**CHEM (bridge pattern) is sufficient for:**
- Static material compatibility (does NMC811 work with EC?)
- Domain-independent reasoning (7 independent bridges)
- Batch predictions (run audit, report results)

**PHARM (categorical runtime) is REQUIRED for:**
- **Dynamic patient state** — Patient's genomics, comorbidities, current meds change over time
- **Real-time morphism reweighting** — As new biomarker results arrive, drug efficacy estimates shift
- **Patient-specific constraints** — Drug A works on EGFR but nephrotoxic (bad for low kidney function)
- **COG interference detection** — Drug B + Drug C don't interact... except in THIS patient with IDH1 mutation
- **Game-theoretic equilibrium** — Find the Nash point: Max efficacy, Min toxicity, Min cost, Min drug count (for THIS patient)

**Categorical runtime enables:**
```
Patient X (object with mutation profile)
  ├─ Drug A (morphism: targets EGFR)
  ├─ Drug B (morphism: targets FLT3)
  ├─ Drug C (morphism: targets BCL2)
  └─ Drug A+B (morphism: synergistic but nephrotoxic for X)

As new kidney function test arrives:
  └─ Reweight Drug A+B morphism (↓ confidence)
  └─ Update game-theoretic equilibrium
  └─ COG detects: "A+B still viable but marginal"
  └─ Suggest alternative: Drug A+C instead
```

**Bridge pattern cannot do this** — it assumes static relationships. Categorical runtime makes relationships **mutable objects** that can be reweighted as data flows in.

| Feature | CHEM (Bridge) | PHARM (Runtime) |
| :--- | :--- | :--- |
| **Model** | Reasoning layer on static data | Execution IS a Category (data + logic unified) |
| **Patient data** | Single query, static result | Streaming updates, dynamic reweighting |
| **Interaction detection** | 5 scorers vote once | COG continuously monitors for collapse |
| **Optimization** | Best path found once | Nash equilibrium updated per new data |
| **Concurrency** | Thread/async orchestration | Monadic morphism composition |

---

### 3. Advanced Math Modules (The "SEC" and "CHEM" Synergy)

By adopting the math modules from `KOMPOSOS-SEC`, the Chemistry/Pharm engine gains unprecedented predictive power:

#### A. COG (Cognitive Interference & Chain Collapse)
- **Current Use (SEC):** Detects exploit chains where two borderline anomalies compose to a "NULL_COLLAPSE."
- **Pharm/Chem Application:** Detects **unintended side effects** or **chemical interference**. If Drug A is safe and Drug B is safe, but their composition yields a NULL_COLLAPSE in the Z2-graded categorical space, a dangerous interaction is predicted before any simulation.

#### B. OPTIMUS (Optimal Transport & Game Equilibrium)
- **Current Use:** Finding Nash equilibrium in defensive/offensive cyber-games.
- **Pharm/Chem Application:** **Optimal Material Selection.** Uses Ollivier-Ricci curvature on the knowledge graph to identify "bottleneck" materials and uses game theory to balance property trade-offs (e.g., Stability vs. Conductivity) as a multi-player Nash game.

#### C. Infinity ($\infty, 1$-Categories & Higher-Order Path Induction)
- **Current Use:** Handling homotopy of paths in SEC.
- **Pharm/Chem Application:** **De Novo Synthesis.** Moving beyond "A + B = C" to "The process of A becoming C." Using Homotopy Type Theory (HoTT) to ensure that the *path* of synthesis is logically induction-stable.

---

### 4. Predictive-Synthetic Duality (Kan Extensions 2.0)

KOMPOSOS-III uses Kan extensions as an "Oracle" layer. In KOMPOSOS-IV, this becomes the **Core Runtime Loop**:

- **Lan (Left Kan):** The "Future" projection. It aggregates all streaming observations to predict the next stable state of a chemical or cyber system.
- **Ran (Right Kan):** The "Teleological" constraint. It works backward from a desired goal (e.g., a non-toxic linker or a secure network state) to define the necessary preconditions.

---

### 3. Integration Strategy: Port CHEM Bridges into PHARM's Runtime

**PHARM's Bridge ABC (in `core/bridge.py`):**
```python
class Bridge(ABC):
    def get_objects(self) -> List[Object]:
        """Return domain entities as categorical Objects."""

    def get_morphisms(self) -> List[Morphism]:
        """Return domain interactions as categorical Morphisms."""

    def score_pair(self, source: str, target: str) -> Dict[str, float]:
        """Return domain-specific compatibility scores."""

    def load(self) -> Dict[str, int]:
        """Load into Category (the runtime)."""
```

**How CHEM ports to this:**

Each CHEM bridge becomes a PHARM Bridge subclass:

```python
# Example: Battery Bridge -> PHARM Runtime
class BatteryBridge(Bridge):
    def get_objects(self):
        # Materials from battery_bridge/material_properties.py
        return [
            Object(name="NMC811", type="cathode", properties={"voltage": 4.3, ...}),
            Object(name="LFP", type="cathode", properties={"voltage": 3.6, ...}),
            ...
        ]

    def get_morphisms(self):
        # Relationships from interaction_scoring.py (5 scorers)
        return [
            Morphism(source="NMC811", target="EC", name="compatible", confidence=0.92),
            ...
        ]

    def score_pair(self, source, target):
        # Call existing interaction_validator.py logic
        return {
            "ion_transport": 0.85,
            "electrochemical_stability": 0.90,
            "interface_compatibility": 0.88,
            "mechanical": 0.92,
            "degradation": 0.79,
            "overall": 0.87
        }

bridge = BatteryBridge("battery")
bridge.load()  # All data now in Category (the runtime)
```

**Advantage:** PHARM's Category IS the runtime. No separate KompososStore, no dual-engine post-hoc verification. Everything streams through one categorical computation.

---

### 4. What PHARM Can Teach CHEM (Improvements Back to our System)

#### A. Tiered Verification (from COG Engine)

PHARM's COG has 5 tiers of increasing computational cost:

| Tier | Cost | What It Does |
|------|------|-------------|
| 0 | ~1ms | Graph lookup (does edge exist?) |
| 1 | ~10ms | Composition + path finding (A→B→C chain) |
| 2 | ~100ms | Sheaf coherence + Kan extensions |
| 3 | ~1s | ZFC dual engine (AGREE/ORPHAN/HOLLOW/REJECT) |
| 4 | ~30s | Full topology + Ricci flow + homology |

**For CHEM:** We could adopt this tiered model:
- **Tier 0:** Does the material pair exist in our database?
- **Tier 1:** Do the 5 scorers agree? (quick vote)
- **Tier 2:** Do multiple bridges agree on the same pair? (cross-bridge validation)
- **Tier 3:** ZFC constraint check (do bond lengths violate NIST bounds?)
- **Tier 4:** Full geometry + Ricci curvature on the materials knowledge graph

**Benefit:** Faster response for simple queries, full analysis only when needed.

#### B. Energy-Based Coherence Checking (from COG energy.py)

PHARM's COG computes "energy" of a claim:
- **Low energy** = coherent with existing knowledge
- **High energy** = contradicts something
- **Resonance** = multiple supporting paths amplify confidence

**For CHEM:** We could track "formation energy errors" as system energy:
- If predicted formation energy conflicts with DFT data → high energy
- If multiple morphism paths predict the same property → resonance (confidence boost)
- If a new material contradicts known electrochemistry → flag it

**Benefit:** Probabilistic rather than yes/no verdicts. Matches how physical systems actually work.

#### C. Patient Profile as Categorical Object (NEW)

PHARM's core innovation for patient-specific medicine:

```python
# Patient becomes a first-class object in the category
patient_obj = Object(
    name="Patient_X_AML_FLT3-ITD",
    type="patient",
    metadata={
        "disease": "AML",
        "mutations": ["FLT3-ITD", "IDH1-R132H"],
        "gene_expression": {...},  # from RNAseq
        "kidney_function": 45,      # eGFR
        "liver_function": "normal",
        "current_meds": ["warfarin"],
        "age": 62,
        "performance_status": 2,
    }
)

# Drug morphism is now patient-specific
morphism = Morphism(
    source="FLT3_Inhibitor_Midostaurin",
    target=patient_obj.name,
    name="targets_FLT3_in_AML",
    confidence=0.87,
    metadata={
        "efficacy_base": 0.87,
        "nephrotoxicity_penalty": -0.15,  # kidney function adjustment
        "drug_interaction_warfarin": -0.05,
        "efficacy_adjusted": 0.67,
    }
)
```

**For CHEM:** Materials + formulations + drug delivery vehicle could be unified:
- Material object: "Li2CO3 cathode coating"
- Drug object: "Sorafenib (RAF inhibitor)"
- Formulation object: "PLGA nanoparticle carrier"
- Patient object: "HCC patient with impaired liver function"
- Morphisms: coating→stability, drug→nanoparticle→patient, with patient-adjusted weights

#### D. COG Interference Detection (for Unexpected Cascades)

PHARM's COG detects when two "safe" morphisms compose into a **collapse**:

```
Drug A safe (confidence 0.9)
Drug B safe (confidence 0.9)
A∘B in patient X → NULL_COLLAPSE → DANGER
```

**For CHEM:** We already found cases where this matters:
- PEO + NMC811 individually fine, combined → degradation (solved with χ parameters)
- Li-metal + Li₃PS₄ individually fine, combined → interface reaction (solved with penalty adjustment)
- LGPS + high-voltage cathode → passivation (solved with electrochemistry fix)

**COG formalizes this:**
```python
# In patient's drug morphism graph
claim = CogClaim(
    source="FLT3_Inhibitor_A",
    target="Patient_X",
    relation="efficacious_in",
    confidence=0.85
)
energy_result = cog_engine.energy_computer.compute(claim)
# If energy > threshold → COLLAPSE → warn clinician
```

**For CHEM:** Apply to material combinations:
```python
claim = CogClaim(
    source="PEO",
    target="NMC811",
    relation="compatible_in_battery",
    confidence=0.85  # individually high
)
# COG checks: in what context does this fail?
# Answer: with high voltage + elevated temperature
```

---

### 5. Convergence: How PHARM + CHEM Bridge for Patient-Specific Oncology

The transition to KOMPOSOS-IV allows us to re-merge the protein/drug logic (previously removed in Phase A cleanup) into a unified framework:

1.  **Unified Namespace:** Use categorical sheaves to map `material_id` (Chem), `pubchem_cid` (Pharm), and `ip_address/port` (Sec) into the same categorical universe.
2.  **Cross-Domain Prediction:**
    *   *Pharm + Chem:* Predicting how a novel MOF (Chem) might act as a drug delivery vehicle (Pharm) using Kan extensions.
    *   *Chem + Sec:* Protecting chemical supply chains (Sec) by verifying the provenance of material precursors (Chem) through ZFC-gated logic.

---

### 5. Recommendation

**Transition Recommended.**

The current KOMPOSOS-III system has hit the limits of the "Bridge Pattern." While successful for 3D materials, the complexity of pharmaceutical interactions and the need for higher-order security in chemical IP requires the move to a **Categorical Runtime**.

**Next Steps:**
1.  **Port the `categorical/streaming_kan.py` and `categorical/enriched_category.py`** to the core runtime loop.
2.  **Integrate the `mof_bridge/interference.py` (COG)** as a global monitoring layer.
3.  **Establish the `oracle/optimizer.py` (OPTIMUS)** as the primary decision engine for de novo design.

---

## 6. Cross-Variant Math Adaptation Strategy (2026-05-16 Update)

### Research Findings: Math Inventory Across KOMPOSOS Variants

After analyzing KOMPOSOS-IV-PHARM and KOMPOSOS-SEC, the key insight is **NOT integration, but selective math adaptation**. Each variant has already evolved its own domain optimizations.

#### A. KOMPOSOS-IV-PHARM Status
**What it has:**
- All 7 chemistry bridges (battery, polymer, metal, ceramic, semiconductor, glass, molecular) — **matches our CHEM system**
- All specialty bridges (PFAS, MOF, cross-bridge) — **matches our CHEM system**
- **Two additional pharmaceutical bridges:**
  - `abpp_bridge.py`: Activity-Based Protein Profiling for experimental validation of drug-target engagement
  - `boltz2_bridge.py`: Structure-based binding prediction (protein-ligand geometry, affinity scoring)

**Key Difference:**
- PHARM bridges are wrapped with pharmaceutical-specific validation (binding affinity, cell viability, toxicity)
- Our chemistry bridges focus on material compatibility and synthesis feasibility
- PHARM's ABPP bridge answers "does it actually bind in a cell?" — the ground-truth validation we lack

**Actionable:** PHARM's strategy of **computational prediction + experimental ground truth** is applicable to materials:
- Our MOF designer generates candidates (like PHARM drug discovery)
- PHARM uses ABPP to validate (wet lab experiment)
- **Materials parallel:** Use Materials Project DFT data or lab synthesis validation as ground truth

#### B. KOMPOSOS-SEC (Cybersecurity) Math Stack
**What it has:**
- All core math: categorical, ZFC, HoTT, topology, geometry, game theory (shared with PHARM/CHEM)
- **Unique additions:**
  - **COG Framework (Cognitive Interference & Chain Collapse)**: Detects when two "safe" entities compose to an unsafe state
  - **Temporal Sheaves**: Time-dependent security state tracking
  - **Boundary Detection & Activity Analysis**: Identifies exploit chain entry points

**How COG works (simplified):**
```
1. Two objects: A (safe in isolation), B (safe in isolation)
2. Morphism A→B exists (looks compositionally sound)
3. But: A∘B produces NULL_COLLAPSE in Z2-graded space
4. COG detects this logical contradiction → alerts user
```

**Why this matters for chemistry:**
- **PEO + high-voltage cathodes**: Both stable individually, but composition degrades
- **Li-metal + Li₃PS₄**: Both known materials, but interface reaction is unexpected
- **Polymer blends**: PC + PET both good, χ > 1.0 means incompatible → phase separation

**COG adaptation for materials:**
Replace the "exploit chain" logic with "degradation pathway" logic:
- Input: Two compatible materials + morphism
- Check: Does composition trigger unexpected side reaction?
- If Z2-collapse detected → flag as "requires validation" (like ABPP in PHARM)

#### C. What We Upgraded That PHARM Might Not Have

**Current KOMPOSOS-III-LAMBDA-max-3D-chem (May 2026):**
- **Research-grade audit:** 259 validated pairs, 95.4% accuracy, 0.966 F1 (Phase 11/13)
- **Dynamic interatomic potentials:** ColabFit empirical bond distributions (replacing static NIST bounds)
- **Flory-Huggins χ enhancements:** 13 new polymer immiscibility parameters
- **Formation energy DFT surrogate:** 175 known values with error estimates (eV/atom)
- **Crystal structure prediction:** 30 types, 100% validation accuracy

**PHARM likely has all chemistry bridges, but:**
- May not have Phase 11/13 extensions (dynamic potentials, χ enhancements)
- May not have calibrated formation energy error estimates
- May not have the latest MOF linker generation with 5-verdict screening

### Recommendation: Selective Math Adoption (Not Full Integration)

**Do NOT integrate all three variants.** Instead:

#### 1. **Adopt COG Interference Detection for Materials** (from SEC)
- **Cost:** ~500 lines porting `cog/energy.py` logic
- **Benefit:** Detect unexpected degradation cascades in material combinations
- **Implementation:**
  - Reframe "exploit chains" as "degradation pathways"
  - Z2-graded space = ionic/electronic stability check
  - NULL_COLLAPSE = unintended side reaction
- **Where:** Add to `oracle/` as `material_cog_detector.py`, wire into compatibility scoring

#### 2. **Adopt PHARM's Ground-Truth Validation Pattern** (from PHARM)
- **What:** ABPP for drugs, DFT/synthesis for materials
- **Cost:** Design new audit format, not code reuse
- **Benefit:** Distinguish "computationally predicted" from "experimentally validated"
- **Implementation:**
  - Mark audit pairs with source: `LITERATURE | DFT | SYNTHESIS_LAB`
  - Add confidence metric based on source diversity
  - Flag predictions that are computational-only (no wet-lab backing)
- **Where:** Extend `audit/run_audit.py` with validation-source tracking

#### 3. **Keep PHARM's Pharmaceutical Bridges As Separate Variant**
- PHARM's ABPP and Boltz-2 are specialized for drugs
- Materials science doesn't need them (no "target engagement" concept)
- **Option:** If you expand into drug delivery (MOF as carrier), then port ABPP logic

#### 4. **Verify SEC's COG Math Matches Our Latest Audit**
- **Action:** Check if `cog/energy.py` handles Z2-graded categorical space correctly
- **Risk:** SEC may use different axioms for "collapse" than our ZFC bridge
- **Validation:** Run COG on 10 known problem pairs (PEO+NMC, LGPS+LFP) — should flag both

### Roadmap: Phased Adoption

**Phase 14 (Q2 2026):** Add COG interference detection
- Port SEC's Z2-graded collapse detection
- Test on 20 problem pairs (materials known to fail)
- Add to compatibility scoring as "Interference Risk" metric

**Phase 15 (Q3 2026):** Implement ground-truth validation tracking
- Audit all 259 pairs: mark as LITERATURE | DFT | SYNTHESIS
- Add confidence intervals by source type
- Report "computational-only" predictions separately

**Phase 16 (Q4 2026):** Extend MOF linker designer with COG
- Use interference detection to flag linkers with unexpected reactivity
- Combine with 5 verdicts → 6-verdict system
- Validate on Kulik test set

**Post-Phase 16:** Conditional PHARM bridge adoption
- If you pursue drug delivery (MOF-as-carrier): integrate ABPP
- Otherwise: keep PHARM as reference for pharmaceutical optimization patterns

### Summary: What to Adapt vs. What to Leave

| Source | Module | Adapt? | Reason |
|--------|--------|--------|--------|
| SEC | COG (Interference) | ✅ Yes | Detects unexpected material degradation |
| SEC | Temporal Sheaves | ❓ Maybe | Useful if tracking synthesis time-evolution |
| SEC | Boundary Detection | ❓ Maybe | Could identify critical material interfaces |
| PHARM | ABPP Bridge | ❌ No | Drug-specific, not materials |
| PHARM | Boltz-2 Bridge | ❌ No | Protein-ligand, not material interfaces |
| PHARM | Upgraded chemistry bridges | ⚠️ Check | May have enhancements we should backport |
| Both | Streaming Kan + Enriched Categories | ✅ Yes | Already planning for categorical runtime |
| Both | Game Theory (OPTIMUS) | ✅ Yes | Material trade-off optimization |

### Final Note: Why Separate Variants Work

The reason KOMPOSOS exists as 70+ variants is **domain-specific optimization trumps unified integration:**
- **PHARM:** Emphasized experimental validation (ABPP) — not relevant to materials
- **SEC:** Emphasized temporal exploit chains — more relevant as material degradation, but still adaptation needed
- **CHEM:** Emphasizes material structure + property data — domain-specific success

**The right move:** Steal the *math* (COG, optimal transport, HoTT), not the *bridges*. Each domain has evolved the perfect bridge architecture for its constraints.

---

## 7. REAL TRANSITION PLAN: INTO KOMPOSOS-IV-PHARM FOR PATIENT-SPECIFIC ONCOLOGY

### Why PHARM IS the Right Target (Not a Theoretical Exercise)

PHARM is ALREADY built as a categorical runtime. It has:
- **Core runtime** (`core/category.py`): Execution IS a Category
- **Simple bridge interface** (`core/bridge.py`): 3 abstract methods
- **COG tiered verification** (`cog/engine.py`): 5 tiers from 1ms to 30s
- **Patient stratification** (BETA-cyber code): mutation profiling, resistance prediction
- **Clinical pipeline**: toxicity assessment, drug combination scoring
- **Game theory** (`bridges/optimus_plugin.py`): Nash equilibrium for multi-objective drugs

**We don't build a new system.** We port CHEM into PHARM.

### Implementation: 4-Week Sprint to MVP

#### Week 1: Port CHEM Bridges into PHARM Bridge ABC

```python
# Each CHEM bridge becomes one PHARM Bridge subclass

from core.bridge import Bridge

class BatteryBridge(Bridge):
    """CHEM battery_bridge → PHARM Bridge"""

    def get_objects(self):
        # From battery_bridge/material_properties.py
        return [
            Object(name="NMC811", type="cathode",
                   properties={"voltage_window": (2.5, 4.3), ...}),
            Object(name="LFP", type="cathode",
                   properties={"voltage_window": (2.5, 3.7), ...}),
            ...
        ]

    def get_morphisms(self):
        # From interaction_scoring.py + interface_validator.py
        return [
            Morphism(source="NMC811", target="EC", name="compatible",
                    confidence=0.92, metadata={"scores": {...}}),
            ...
        ]

    def score_pair(self, source, target):
        # Call existing 5-scorer logic
        from battery_bridge.interaction_scoring import score_compatibility
        return score_compatibility(source, target)

# Load into PHARM runtime
battery_bridge = BatteryBridge(name="battery")
battery_bridge.load()  # All data now in Category

# Repeat for 6 other bridges (polymer, metal, ceramic, semicond, glass, molecular)
```

**Effort:** ~100 lines per bridge × 7 = ~700 lines. Mostly copy-paste.

**Test:** Verify 259 pairs + accuracy metrics reproduce in PHARM Category.

#### Week 2: Add Patient Profile Object Type

```python
# Patient as categorical object

class PatientBridge(Bridge):
    """Patient profiles with genomic metadata"""

    def get_objects(self):
        # Load from EHR or ClinicalTrials.gov
        return [
            Object(
                name="Patient_AML_001",
                type="patient",
                metadata={
                    "disease": "AML",
                    "mutations": ["FLT3-ITD", "IDH1-R132H"],
                    "gene_expression": {...},
                    "kidney_function": 45,
                    "liver_function": "normal",
                    "current_meds": ["warfarin"],
                    "age": 62,
                    "ecog_status": 2,
                }
            ),
            ...
        ]

    def get_morphisms(self):
        # Drug → Patient interactions
        return [
            Morphism(
                source="FLT3_Inhibitor_Midostaurin",
                target="Patient_AML_001",
                name="targets_mutation",
                confidence=0.87,  # Base efficacy
                metadata={
                    "base_efficacy": 0.87,
                    "nephrotoxicity": -0.15,  # kidney adjust
                    "warfarin_interaction": -0.05,  # drug interaction
                    "age_adjustment": -0.02,  # elderly penalty
                    "adjusted_efficacy": 0.65,
                }
            ),
            ...
        ]

    def score_pair(self, source, target):
        # Patient-specific adjustment logic
        return {
            "base_efficacy": self.base_efficacy(source),
            "patient_adjustments": self.compute_adjustments(target),
            "final_efficacy": self.adjusted_efficacy(source, target),
        }
```

**Test:** For Patient X, retrieve top 5 drugs ranked by patient-adjusted efficacy.

#### Week 3: Wire COG Interference Detection

PHARM's COG already exists. Wire it to detect:
1. **Drug-drug interactions** (Drug A + Drug B → collapse in this patient?)
2. **Material-material interactions** (PEO + NMC811 → collapse under what conditions?)

```python
# In patient's morphism graph
from cog.engine import CogEngine

patient_claim = CogClaim(
    source="Midostaurin",
    target="Patient_AML_001",
    relation="efficacious_in",
    confidence=0.65
)

# COG computes energy (coherence with patient's other meds, comorbidities)
energy = cog_engine.energy_computer.compute(patient_claim)
if energy.total_energy > COLLAPSE_THRESHOLD:
    alert_flag = "DANGEROUS_IN_THIS_PATIENT"
    # e.g., midostaurin + warfarin → bleeding risk
```

**Test:** COG correctly flags 10 known drug-drug interactions.

#### Week 4: Integrate OPTIMUS Game Theory

PHARM's OPTIMUS already exists. Reframe for patient-specific optimization:

```python
# Multi-objective game for this patient
game_state = {
    "player_1_efficacy": 0.87,      # Higher is better
    "player_2_toxicity": 0.15,      # Lower is better
    "player_3_cost": 0.20,          # Lower is better
    "player_4_drug_count": 0.10,    # Lower is better

    # Patient-specific weights
    "weights": {
        "efficacy": 0.50,           # Efficacy most important
        "toxicity": 0.30,           # Then safety
        "cost": 0.15,               # Then cost
        "drug_count": 0.05,         # Fewer drugs nice but not critical
    }
}

# Find Nash equilibrium: best drug combo for THIS patient
nash_point = optimus_plugin.find_equilibrium(game_state)
# e.g., [Midostaurin, Venetoclax, Low-dose AraC]
#        efficacy=0.78, toxicity_adjusted=0.12, cost=$180K/yr, 3 drugs
```

**Test:** Recompute equilibrium within 10 seconds of new biomarker data.

---

### Post-MVP: Clinical Validation

**Once MVP works:**
1. **Validation set:** 50 real AML patients from TCGA/GDC
2. **Metric:** Do our recommended drug combos match actual clinical responses?
3. **Regulatory:** FDA guidance requires explainability (we have derivation traces)
4. **Publication:** Nature Medicine / JCO Precision Oncology track

---

### Why This Works (Honest Assessment)

**Strengths:**
- PHARM runtime already exists (not building from scratch)
- CHEM bridges are proven (95.4% accuracy)
- COG + OPTIMUS already built (no new math needed)
- Patient-specific weighting natural extension of existing code

**Risks:**
- Clinical liability (must involve MD approval)
- PHARM's documentation sparse (will need to reverse-engineer parts)
- Regulatory (FDA approval path unclear)
- Validation on real patients (6+ months)

**Timeline:** 4 weeks MVP, 4-6 months clinical validation
